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AIM 
To assess the patient reported Health related quality of life (HRQOL) and 
Neurocognitive function (NCF) in high grade glioma patients willing to have adjuvant 
treatment after surgery in Christian Medical College Hospital, Vellore. 
 
OBJECTIVES 
Primary Objective: 
To determine the health related quality of life (HRQOL) and neurocognitive 
function (NCF) using standard tools pre radiotherapy, post radiotherapy and at first 
follow up after adjuvant chemotherapy. 
Secondary Objectives: 
1. To evaluate the correlation between HRQOL and NCF. 
2. To predict disease recurrence from impairment in HRQOL and NCF before 
evident clinical and radiological features of recurrence. 
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INTRODUCTION 
 
 
Tumours of the brain and Central nervous system (CNS) comprise a group of 
infrequent and heterogeneous tumours with respect to genetics and biology. Central 
nervous system neoplasms constitute 1-3% of all malignancies. The incidence of brain 
tumours has been slowly increasing at an average rate of 1.1% per year. Depending 
upon the age, histology and site in the CNS, these tumours have varied presentations 
and contrasting clinical outcomes. Most of the patients present with headache, 
seizures or neurological deficits.(1) 
 
Among CNS neoplasms, gliomas are the most common tumours. These tumours 
include astrocytomas, oligodendrogliomas, and ependymomas. Malignant gliomas 
comprise Glioblastoma – IDH wild type and mutant type [World Health Organization 
(WHO) grade IV], diffuse midline glioma (WHO grade IV), anaplastic astrocytoma – 
IDH mutant (WHO grade III), anaplastic oligodendroglioma – IDH mutant and 1p/19q 
co-deleted (WHO grade III) and anaplastic pleomorphic xanthoastrocytoma (WHO 
grade III).(2) 
 
 Magnetic Resonance Imaging (MRI) of brain with contrast is the diagnostic modality 
of choice when a brain tumour is suspected. The current standard therapy is maximal 
safe neurosurgical resection, removing as much tumour tissue as possible without 
causing new neurological deficits. Adjuvant therapy is based on the histopathological 
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report and if high grade requires concurrent chemo radiotherapy followed by adjuvant 
chemotherapy.(3) 
 
Overall survival and mortality rates are traditionally used as the key indicators of 
population health in relation to any disease condition especially in malignancies. 
However, a paradigm shift in the concern of health came in early 1990s when WHO 
introduced the concept of health related quality of life. HRQOL is a multi-dimensional 
concept that includes domains related to physical, mental, emotional, social 
functioning and also includes other domains such as cognitive functioning, sexuality and 
spirituality.(4) 
 
It goes beyond direct measures of population health, life expectancy, and causes of 
death. Currently all oncological treatment strategies are directed at maintaining a 
reasonable quality of life in addition to the survival and disease free outcomes. 
Especially in brain tumour patients, the HRQOL will be affected due to brain 
parenchymal dysfunction at the time of presentation itself. So the treatment should be 
aimed at improving the quality of life and maintaining it during the period of 
survivorship. In brain tumour patients, apart from the health related quality of life issues, 
deterioration in neurocognitive functioning is also an area of serious concern. Literature 
review has shown that there is improvement in both health related quality of life and 
neurocognitive functioning as a result of the treatment. Also it has been reported in 
certain studies that there is direct correlation between neurocognitive functioning and 
quality of life.(5,6) 
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There are very few Indian studies that looked at the effects of treatment on HRQOL 
and neurocognitive functioning of high grade glioma patients. The present study is 
aimed at assessing the changes in HRQOL reported by patient and the neurocognitive 
functioning after surgery, during the course of adjuvant treatment and in follow up 
period. Deterioration in either of the parameters can give early insight about disease 
recurrence during the follow up period. To determine the HRQOL and NCF status, 
there are many validated standard patient reported questionnaires like FACT-G, 
FACT-Br, EORTC QLQ C-30, SF-36, MMSE, and MOCA etc.(7) 
 
REVIEW OF LITERATURE 
HISTORY 
The history of treating malignant gliomas dates back to the middle of the 19th century 
and parallels landmark advances in modern surgical technique and the clinical 
discipline of neurology. In efforts to improve surgical outcome, Harvey Cushing 
(1926), who had contributed major advances in surgical technique, pioneered the first 
histological grading scheme for gliomas and correlated it with clinical outcome. 
Radiation therapy was introduced soon thereafter in an attempt to cure these 
infiltrative tumours. Although clearly improving the median survival in intermediate-
grade gliomas by many months and Glioblastoma by several months, the addition of 
radiation ultimately failed to alter long-term outcome.(8) 
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With the advent of chemotherapy in blood and solid malignancies, agents that could 
penetrate the blood–brain barrier were added to the treatment protocols of malignant 
gliomas. Nitrosourea-based chemotherapy, in combination with surgery and radiation 
therapy, emerged as the only regimen that improved median survival. Although 
nitrosoureas became the standard therapy for malignant gliomas, patients were not 
cured with this or any other cytotoxic agents, regardless of tumour grade.(9) However, 
with the advancements in molecular technology that can provide more insight into the 
tumour biology of gliomas and thereby with targeted therapy, more meaningful 
treatment strategies will emerge in management of gliomas in the coming years. 
 
EPIDEMIOLOGY 
 
The incidence rates of high grade gliomas vary significantly by histopathological type, 
age at diagnosis, gender, race, ethnicity, and geographic location. In general, these 
tumours are more common with increasing age, male gender, white race, and non-
Hispanic ethnicity.(2) 
 
In adults, the most common type of glioma is Glioblastoma, which ranges in age-
adjusted annual incidence rate from 0.6 to 3.7 per 100,000 persons depending on 
reporting country/organization. The highest incidence of Glioblastoma is among those 
aged >64 years. The age at diagnosis tends to be higher for primary Glioblastoma 
(mean age of 55 and median age of 64) than for secondary Glioblastoma (mean age of 
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40 years). The median age of diagnosis for anaplastic astrocytoma and anaplastic 
oligodendroglioma varies from 50 – 55 years.(2) 
Geographic and Temporal differences: 
Gliomas constitute the largest proportion of malignant brain tumours; hence it is 
largely reflected in reported overall brain cancer incidence. Incidence is highest in 
Europe, where its annual age-standardized rate (ASR) is 5.5 per 100,000 persons, then 
North America (5.3 per 100,000 persons), Northern Africa (5.0 per 100,000 persons), 
Western Asia (5.2 per 100,000 persons), and Australia/New Zealand (5.3 per 100,000 
persons). It is the lowest in sub-Saharan Africa (0.8 per 100,000 persons), South-
Central Asia (1.8 per 100,000 persons), and Oceania (0.5 per 100,000 persons)(1) 
(Figure 1). 
 
Incidence was generally higher in men than in women, with a male to female ratio of 
2.7:1. Large differences were observed between the white and black populations of the 
US, with an almost 2-fold higher incidence among whites relative to blacks (8.3 v/s 
4.4 in white and black men and 6.0 v/s 3.6 in women, respectively) (Figure 3). 
Overall, it is difficult to determine whether these geographical and temporal 
differences in glioma incidence are “true” or caused by variation in data collection 
technique, advent of CT and MRI or coverage of surveillance methods(1) (Figure 2). 
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Figure 1: Age-standardized incidence rates of malignant brain tumours per 
100,000 persons in 2012 by country. According to GLOBOCAN: 
 
 
 
 
 
Figure 2: Age-standardized incidence rates of malignant brain tumours per 
100,000 men (a) and women (b) from 1960 to 2005. According to GLOBOCAN 
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Figure 3:Truncated age-standardized incidence rates of brain and CNS cancers 
(per 100,000, ages ≥15 y, world standard), 2003–2007 by sex.(1) 
 
 
 
 
 
CLASSIFICATION OF BRAIN TUMOURS 
The 2016 World Health Organization Classification of Tumours of the Central 
Nervous System molecular parameters in addition to histology define tumour entities, 
thereby formulating a new concept for how CNS tumour diagnoses should be 
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structured in the molecular era. It presents major restructuring of the diffuse gliomas, 
medulloblastomas and other embryonal tumours, and added new entities that are 
defined by both histology and molecular features, including Glioblastoma, IDH 
wildtype and IDH-mutant; diffuse midline glioma, H3 K27M–mutant (Figure 4). The 
term glioblastoma multiforme was introduced in 1926 by Percival Bailey and Harvey 
Cushing, based on the idea that the tumour originates from primitive precursors of 
glial cells (glioblasts) and the highly variable appearance due to the presence of 
necrosis, haemorrhage and cysts (multiform). However the name was recently 
changed to Glioblastoma.(10) 
Figure 4: WHO CLASSIFICATION OF HIGH GRADE GLIOMAS:
 
 
RISK FACTORS 
Little is known about the etiological factors of brain tumours. Other than genetic risk 
factors, ionizing radiation exposure is known to increase the risk whereas allergy and 
atopy decreases the risk. Exposure to non-ionizing radiation, especially 
radiofrequency fields from mobile phones but also low frequency fields, infections 
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with some viruses, use of hormonal contraceptives, hormone replacement therapy, 
statins, vitamin D level, alcohol, height, BMI, and occupational exposures have been 
investigated, but no firm conclusions can be drawn at present(2) (Figure 5). 
 
Figure 5: Results of selected recent analyses of potential risk factors for gliomas 
 
 
 
 
Genetic factors: 
Several inherited, monogenic Mendelian cancer syndromes are associated with 
increased incidence of specific glioma subtypes(2) (Figure 6). 
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Figure 6: Monogenic Mendelian disorders associated with increased risk of glioma 
 
 
 
 
 
CLINICAL PRESENTATION 
The presenting symptoms and signs of brain tumours are divided into those associated 
with a mass effect and increased intracranial pressure and focal neurological 
symptoms. The most common presenting symptom is headache, and approximately 
20% of patients with supratentorial tumours present with seizures.(3) Frontal lobe 
lesions present with personality changes, slowing of contralateral hand movements, 
contralateral spastic hemiplegia, mood changes, difficulty in adapting to new 
situations, loss of initiative, dysphagia, lip and tongue movements abnormality, 
apraxia, if dominant lobe is involved. Temporal lobe lesions present with impairment 
of recent memory, homonymous quandrantanopsia, auditory hallucination, aggressive 
behaviour, impaired perception of verbal command, fluent-Wernicke-like aphasia.  
Parietal lobe lesions are characterised by mild hemiparesis, mild to severe sensory 
loss, homonymous hemianopia, visual inattention, alexia, dysgraphia, and other forms 
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of apraxia. Occipital lesions have contralateral homonymous hemianopia, visual 
aberrations, and cortical blindness.(11) 
 
PATHOLOGY, GENETICS AND MOLECULAR 
BIOLOGY 
 
High grade gliomas arise from supporting glial cells in the brain. The predominant cell 
type determines the pathological classification. Tumours are graded according to the 
World Health Organisation (WHO) grading system (Grade I to IV). HGGs comprise 
of WHO grade III and IV tumours. Multiple subtypes have been identified which may 
alter response to treatment and prognosis. These include subtype III which comprises 
anaplastic astrocytoma, oligoastrocytoma, and anaplastic oligoastrocytoma as well as 
subtype IV which includes Glioblastoma, Glioblastoma with oligodendrocyte 
component and gliosarcoma. Grade III tumours are diffusely infiltrating astrocytomas 
with focal or dispersed anaplasia and a marked proliferative potential with increased 
cellularity, distinct nuclear atypia and high mitotic activity while Grade IV tumours 
show cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular 
thrombosis, microvascular proliferation and necrosis. Grading is determined by the 
most malignant part of tumour.(2, 10) 
Glioblastoma:  
Inherited tumour syndromes such as Li-Fraumeni and Turcot syndromes have a 
genetic predisposition to primary brain tumours however accounts for less than 2% of 
malignant gliomas. Inheritance is autosomal dominant trait, so mostly known and 
easily documented in family history. However, the majority of brain tumours are 
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sporadic in nature. A great achievement of yester years has been the classification of 
malignant gliomas based on gene expression patterns. Microarray techniques on the 
DNA, RNA and protein level have established new classifications portraying the 
heterogeneity of Glioblastomas. It is hoped that further molecular characterization of 
glioma subtypes will lead to the application of customized therapy to subgroups and 
improve the effectivity of treatments.(12) 
Based on the analysis of 206 patient samples, Verhaak et al published four subgroups 
of Glioblastoma, named Proneural, Neural, Classical and Mesenchymal, which differ 
by gene expression, clinical characteristics, response to therapy and outcomes. 
 
Next generation sequencing and analysis of gene expression profiling and epigenetic 
methylation have shown – as expected – that Glioblastomas are extremely diverse in 
any dimension, so that every tumour has to be considered as unique. Two tissue-based 
biomarkers have successfully been adopted for clinical use and provide 
prognostic/predictive information for patients with Glioblastoma: the status of O6-
methyl guanine methyl-transferase (MGMT) promoter (methylated or not) and the 
isocitrate dehydrogenase (IDH) 1 and 2 mutations (Figure 7). The MGMT gene 
encodes the DNA-repair protein O6-methylguanine methyl-transferase. A methylated 
promoter of the MGMT gene has been shown to correlate with an increased survival in 
patients with Glioblastoma: Epigenetic silencing of the MGMT gene by promoter 
methylation is associated with diminished DNA-repair activity. MGMT-promoter 
methylation correlates significant with outcome to the alkylating chemotherapeutic 
substance Temozolomide (TMZ) whereas high levels of MGMT 8activity in cancer 
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cells create a resistant phenotype by blunting the therapeutic effect of alkylating 
agents.(13) 
 
Glioblastoma patients with tumours with IDH1 or IDH2 mutations have a better 
outcome than those with wild-type IDH genes. A mutation either at Arg 132 (IDH1) 
or at Arg172 (IDH2) leads to a 300 fold increase of D-2-HG (hydroxyglutarate) in the 
respective cells which interferes with epigenetic control and thus changes the 
expression of multiple genes. Furthermore, IDH1/2 mutations were defined as a 
reliable genetic marker for secondary Glioblastomas, which developed from lower-
grade gliomas.(10, 14, 15) 
Figure 7: IDH Wild type and IDH Mutant Glioblastoma 
 
 
 
Anaplastic Astrocytoma: 
WHO grade III anaplastic astrocytomas are now divided into IDH-mutant, IDH-wild 
type and NOS categories. Mostly the great majority falls into the IDH-mutant 
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category if IDH testing is available.  If Immunohistochemistry for mutant R132H 
IDH1 protein and sequencing for IDH1 codon 132 and IDH2 codon 172 gene 
mutations are both negative, or if sequencing for IDH1 codon 132 and IDH2 codon 
172 gene mutations alone is negative, then the lesion can be diagnosed as IDH wild 
type. If IDH testing is not available or cannot be fully performed, the resulting 
diagnosis would be anaplastic astrocytoma, NOS. WHO grading is retained for both 
IDH-mutant and IDH-wildtype astrocytomas, however prognoses of IDH-mutant 
cases appear more favourable.(10) 
 
Anaplastic Oligodendroglioma: 
 
The diagnosis of anaplastic oligodendroglioma requires the demonstration of both an 
IDH gene family mutation and1p/19q co-deletion. In the absence of testing 
capabilities or in the setting of inconclusive genetic results, a histologically typical 
anaplastic oligodendroglioma should be diagnosed as NOS. (10) 
 
Other astrocytomas: 
 
Anaplastic pleomorphic xanthoastrocytoma, WHO grade III, has been added to the 
2016 CNS WHO Classification as a distinct entity, as opposed to the descriptive title 
of pleomorphic xanthoastrocytoma with anaplastic features in the past. Grading of a 
pleomorphic xanthoastrocytoma as anaplastic requires 5 or more mitoses per 10 high-
power fields; necrosis may be present, but the significance of necrosis in the absence 
of elevated mitotic activity is unclear.(10) 
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TREATMENT OF MALIGNANT GLIOMAS 
Treatment of malignant or high grade gliomas includes combined modality approach 
characterised by surgery, radiotherapy and chemotherapy which includes a team of 
neurosurgeon, radiation oncologist, and medical oncologist and preferably a 
neuropsychologist.   
Surgery: 
Surgery is the initial therapeutic approach for tumour debulking and obtaining tissue 
for histological diagnosis. Maximal safe resection without compromising the 
neurological function is current the gold standard of care. When maximal safe 
resection is not feasible due to specific tumour location in eloquent areas, a 
stereotactic biopsy is recommended.(16) 
Radiotherapy: 
The current standard of care adjuvant therapy in high grade glioma has been 
formulated by Stupp et al. It includes radiotherapy with concurrent chemotherapy 
followed by adjuvant chemotherapy. Fractionated focal radiotherapy (60Gy, 30–33 
fractions of 1.8–2Gy, or equivalent doses/fractionations) is the standard treatment 
after resection or biopsy.(17) Escalating doses beyond 60Gy has not been shown to be 
of value. In elderly patients or patients with poor performance status, shorter hypo 
fractionated regimens (e.g. 40Gy in 15 fractions) are commonly proposed.(16) 
Radiotherapy can be delivered using conventional or conformal techniques in a 
Telecobalt or Linear Accelerator respectively. The conventional or conformal 
radiotherapy for high grade glioma is delivered daily, 5 days a week for six weeks. 
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The target volume for radiation therapy includes the tumour bed and the surrounding 
oedema plus a security margin, as the oedema zone is a dense tumour infiltration zone 
due to the infiltrative growth pattern of high grade gliomas. A randomised trial in 
1970s has shown survival benefits in high grade glioma with post-operative whole 
brain radiotherapy. Subsequently, many studies by different groups especially the 
Brain Tumour Co-operative group (80-01) compared whole brain irradiation with 
partial brain irradiation and concluded that there was no advantage with whole brain 
radiotherapy.(18) As a result, it became standard to treat HGG with partial-brain RT 
treatment. The introduction of computerized tomography (CT) and magnetic resonance 
imaging (MRI) has contributed largely to improve the accuracy of tumour delineation. 
The three-dimensional (3D) conformal radiation technique makes partial-brain irradiation 
for glioma possible and reduces neurotoxicity.(19) 
However, the optimal treatment volume for Grade 3 gliomas and Glioblastoma remains 
controversial and varies among cooperative groups. For example, the guidelines of the 
Radiation Therapy Oncology Group (RTOG) refer to a two-phase treatment at 59.4 - 
60Gy, where the phase 1 clinical target volume (CTV) includes postoperative 
peritumoural oedema plus a 2cm margin, followed by phase 2 volume defined as the 
residual tumour plus a 2cm margin (as per RTOG 0525 and RTOG 0825 trials).(20) 
Conversely, the European Organization for Research and Treatment of Cancer (EORTC) 
describes a single-phase treatment pattern with 2–3 cm dosimetric margins around the 
tumour (as evaluated by MRI), because 80%–90% of treatment failures occur within this 
margin. (Figures 8-10) The University of Texas MD Anderson Cancer Centre uses a 2 cm 
margin around the gross tumour volume (GTV), which consists of the resection cavity 
and any residual contrast enhancing tumour, but ignoring any oedema.(19–22) 
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Figure 8: [A]: Phase 1 GTV includes postoperative peritumoural oedema based 
on the axial T2 fluid-attenuated inversion recovery sequence (red line); the phase 
1 CTV (green line) includes postoperative peritumoural oedema plus a 2cm 
expansion in all directions(20) 
 
Figure 9: [B]: Phase 2 GTV includes the surgical cavity and residual 
enhancement based on the axial T1 sequence with gadolinium (red line) and 
phase 2 CTV is a 2cm expansion in all directions (green line) respecting 
anatomical boundaries.(20) 
 
Figure 10:[C]: Single phase treatment - The GTV includes surgical cavity and 
residual enhancement based on the axial T1 sequence with gadolinium (red line) 
and CTV is a2 cm expansion in all directions (green line) respecting anatomical 
boundaries.(20) 
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Chemotherapy: 
According to Stupp et al, concomitant chemotherapy using Temozolomide is the 
current standard of care. Temozolomide is administered orally during the course of 
radiotherapy on all days with adequate fasting and anti-emetic medications. The 
dosage of Temozolomide during concurrent therapy is 75mg/m2. During the 
maintenance phase or adjuvant therapy, Temozolomide dosage is 150-200mg/m2 
administered for continuous 5 days every 28 days for 6 cycles.(16,17) 
 
Continuous daily administration of TMZ will induce profound lymphocytopenia with 
CD4 counts <200/mm3 and this is associated with an increased risk of opportunistic 
infections mainly, Pneumocystis pneumonia. Hence, prophylactic administration of 
Trimethoprim-sulfamethoxazole is recommended during the concomitant phase 
whereas it is not required in the maintenance phase. The blood counts should be 
monitored weekly and chemotherapy should be temporarily suspended in the case of 
thrombocytes <75.000/mm3 or a neutrophil count of <1500/mm3. In addition, 
monitoring of liver functions is also suggested due to the high incidence of acute 
hepatic dysfunction characterised by elevated enzymes.(23,24) 
 
Figure 11: Summary of guidelines for the management of high grade glioma 
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PROGNOSIS 
Despite advances in management, a diagnosis of HGG still carries a dismal prognosis. 
The median survival without any treatment is less than six months, but with treatment, 
this increases up to 18 months. The median survival for patients with grade III 
tumours is ∼3 years. Glioblastomas are extremely aggressive and are associated with 
a median survival of 12 to 18 months. Increasing age, poor initial neurology, poor 
general condition as evidenced by Karnofsky Performance score(KPS) and absence of 
MGMT methylation have all been associated with poor survival. Patients who 
undergo surgery and chemo-radiotherapy have shown better long term benefits. Why 
certain groups of patients survive longer than others is still unknown. Death is usually 
due to cerebral oedema and raised intracranial pressure.(25–27) 
 
Figure 12: Kaplan-Meier plots of 10-year survival by time period for patients 
with WHO grade I-IV astrocytomas(28) 
 
 
34 
 
Figure 13: From: Survival trends of grade I, II, III and IV astrocytoma patients and 
associated clinical practice patterns between 1999 and 2010: A SEER-based analysis(29) 
 
 
 
Figure 14: Recursive Partitioning Analysis of High grade glioma based on KPS, 
age of patient and treatment(30)
 
 
HEALTH RELATED QUALITY OF LIFE 
Life expectancy and causes of death have traditionally been used as key indicators of 
population health. While these indicators provide critical information about the health 
status of populations, they do not offer any information about the general quality of 
life. When quality of life is considered in the context of health and disease, it is 
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commonly referred to as health-related quality of life (HRQOL) to differentiate it 
from other aspects of quality of life.  In 1995, the WHO recognized the importance of 
evaluating and improving people’s quality of life.  A causal model with clear 
distinctions between the most common approaches used to assess HRQOL was 
developed by Wilson and Cleary in 1995.(4,31) (Figure 15) 
 
Figure 15: Revised Wilson and Cleary model for health-related quality of life. 
Adapted from “Linking Clinical Variables with Health-Related Quality of Life: 
A Conceptual Model of Patient Outcomes,” by I.B.Wilson and P.D.Clearly, 1995. 
Copyright by JAMA 
 
 
 
HRQOL is a multi-dimensional concept that includes domains related to physical, 
mental, emotional, social functioning and may also include other domains such as 
cognitive functioning, sexuality and spirituality. It goes beyond direct measures of 
population health, life expectancy, and causes of death. 
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HEALTH RELATED QUALITY OF LIFE IN CANCER PATIENTS 
Over the decades, Oncology has become an important area for researches on HRQOL. 
Patients with cancer exhibit many symptoms and losses of functional ability. Many of 
these symptoms and functions are not measureable with laboratory tests or imaging 
procedures and it is necessary to rely on the patients’ self-reports. Some examples are 
role functioning, physical and social functioning, sense of emotional wellbeing, health 
related issues, curtailment of daily activities, pain, and fatigue. 
 
Most of the studies of HRQOL in cancer survivors were concentrated on patients with 
Breast cancer, Prostate cancer, Colorectal cancer, Lung cancer and Brain tumours. A 
review of several trials assessing the HRQOL in cancer patients have shown that, the 
quality of life is affected not only by the disease, but also the psychological impact on 
patients, and to some extent, the treatment related side effects.(5) 
 
Women treated for breast cancer have problems associated with their general 
appearance, sexual problems, lymphedema numbness, muscle stiffness, aches and 
pains, tendency to take naps, and difficulty concentrating, affecting their overall 
physical functioning and well-being. Similar deterioration of quality of life was noted 
in prostate and colorectal cancer patients. However, a paradigm shift with better 
results was noted in their quality of life with the present treatment protocols 
supporting organ preservation in eligible patient groups. Certain studies have shown 
that, patients experiencing recurrence of disease suffered greater decrements in 
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HRQOL, particularly in symptoms and physical functioning, than did patients with 
metastatic disease at presentation. (5,32) 
According to certain reviews, Patients who have answered HRQOL questionnaires 
report that there is better exchange of information between them and their physicians 
and nurses and that they are more satisfied with their overall interaction with the 
healthcare providers than patients who have not answered questionnaires. It has added 
to an improvement in their HRQOL scores. Understanding of the patterns of HRQOL 
is important for patient information and shared decision-making. Patients need to 
know what their HRQOL outcome will be during therapy, and also during palliative 
care. Individual problems may be identified with the assistance of QOL questionnaires 
prior to, during and subsequent to therapy; therefore, supportive care may be initiated. 
For an effective evaluation of treatment outcomes, it is crucial to identify changes in 
HRQOL that occur as result of the tumour, the therapy or other issues. In brain tumour 
patients, apart from the health related quality of life issues, deterioration in 
neurocognitive functioning is also an area of serious concern.(33) 
 
HEALTH RELATED QUALITY OF LIFE IN BRAIN TUMOUR PATIENTS 
 
Traditionally, the goals of brain tumour management included patients’ overall 
survival, progression-free survival and overall radiographic response, which are 
achieved by maximal safe resection of tumours followed by adjuvant treatment based 
on histopathology. Accordingly, physicians up until recently have focused on 
prolonging the disease-free state of patients rather than improving their HRQOL. 
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Among the treatment modalities, surgical tumour removal has been the standard for 
brain tumour management. However, surgery and adjuvant therapy often resulted in 
various degrees of postoperative complications, leading to the deterioration of 
physical, emotional, and social functions. This can ultimately result in a reduction of 
HRQOL for brain tumour patients.(34) 
 
There has been a recent shift in the paradigm of healthcare in brain cancer patients. 
According to this new paradigm, survival not only means the absence of disease, but 
also includes physical, social, and mental well-being of an individual. Moreover, in 
line with this new perspective, the main objective of brain tumour management had 
been expanded to include not only increasing the overall survival, but also improving 
HRQOL. Therefore, treatment strategies for brain tumours started focusing on 
enhancing patients’ HRQOL. Consequently, HRQOL has become an important 
secondary outcome measure in randomized controlled trials for primary brain tumour. 
HRQOL constitutes an alternative for OS as a patient-centred endpoint, because 
HRQOL also assesses direct patient benefit. This endpoint is particularly meaningful 
because it reflects the patients’ perspective. It may also be a surrogate endpoint for OS 
if the treatment effect on HRQOL predicts a survival benefit. Certain studies did show 
that HRQOL is prognostic for OS. Moreover, in patients with limited survival 
expectations, such as glioma patients, maintenance or improvement of HRQOL can be 
considered as important as prolonging survival.(32) HRQOL is assessed using self-
reported, validated questionnaires, addressing physical, psychological, emotional, and 
social issues. In addition to generic HRQOL instruments, disease-specific 
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questionnaires have been developed. As early as in 1980s the quality of life of brain 
tumour patients was considered significant by a group of physicians. They started to 
introduce the new concept such that judgement must be made that balances quality of 
life against quantity of life. Initial studies used Karnofsky performance scores (KPS) 
for determining quality of life and most of the studies validated that even though it is a 
subjective assessment by physician it correlated with patients’ general quality of 
life.(35) 
 
Both LGG and HGG patients, fatigue is one of the most common symptoms and, 
therefore, one of the leading symptoms of decreasing quality of life. Clinically, 
significant symptoms of depression have been shown to be present in a significant 
portion of HGG patients, and this is probably higher than the prevalence in the general 
cancer population. Thus, depressive symptoms are a serious clinical issue negatively 
affecting HRQOL in these patients and are related to shorter survival in LGG patients.  
 
HEALTH RELATED QUALITY OF LIFE IN HIGH GRADE GLIOMAS 
As one would expect, the majority of newly diagnosed HGG patients have a 
significantly impaired level of HRQOL, compared with healthy controls. Systematic 
pre-treatment evaluation of HRQOL in clinical trials illustrates clearly that the disease 
itself has a major negative impact and that treatment may improve HRQOL. However, 
the side effects of treatment may seriously hamper cognitive functioning and HRQOL, 
especially in long-term survivors who have no active disease.(5, 36) 
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HGG patients experience the same level of HRQOL as those with other neurological 
diseases of the central and peripheral nervous system. When comparing HGG patients 
with other cancer patients, such as those with lung cancer, similar quality of life 
results were found. Several tumour-related factors in HGG patients can have an 
impact on perceived HRQOL. (37) 
 
Comparison of quality of life in patients with high grade glioma and metastatic brain 
tumours have been attempted in some trials using standard questionnaires; however 
there is paucity of knowledge to reach a definite conclusion on it and at the same time 
there was conflicting results in different studies. In one of the largest published study 
by Nicholas Chiu et al, it was noted to have a statistically significant difference in the 
social and functional well-being scales, where metastatic brain tumour patients 
performed poor compared to HGG. Though there was no statistically significant 
differences in other aspects of quality of life including cognition, a trend was noted 
where metastatic brain tumour patients’ scores were lower compared to high grade 
glioma.(37) 
 
The role of HRQOL and its assessment are very different in low grade glioma 
compared to those with glioblastoma or other high grade gliomas due to key 
differences in average age of presentation, treatment, clinical course of the disease, 
and ultimately prognosis. Quality of life in low grade glioma patients is better 
compared to high grade counterparts in all domains of assessment however the long 
term follow up data have shown a trend of subsequent decline in scores owing to 
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neurocognitive dysfunction especially in post radiotherapy patients. There are no trials 
that compared the quality of life outcomes in low grade versus high grade gliomas 
directly, but information from available literature has shown favourable results in low 
grade glioma. However between patients diagnosed with glioblastoma and patients 
diagnosed with anaplastic astrocytoma, no differences in HRQOL scores existed at the 
time of diagnosis.(38) 
 
Next to grade, tumour size and location correlate with HRQOL. Large tumours, 
tumours in the right cerebral hemisphere and tumours located anteriorly in the brain 
are associated with poorer HRQOL scores. Also disease-specific signs and symptoms 
have a major impact on quality of life. Neurological signs and symptoms, such as 
seizure frequency, motor deficits, and functional status, have been proven to diminish 
HRQOL. Surprisingly, no deleterious effect of dysphasia on HRQOL has been 
established. (6) 
 
A prospective study of quality of life in adults with newly diagnosed high-grade 
gliomas by Brown et al, which looked at relation of performance score and patient 
reported health related quality of life has shown that performance status is closely 
related to QOL.(39) The variables analysed in the study were fatigue, day time 
somnolence, and depression and Eastern Co-operative Oncology Group performance 
scores. This was consistent with the findings of Mackworth et al, Klein et al and 
Osoba et al, where QOL was found to have significant relation with KPS.(5,40) The 
largest randomised control trial on HRQOL in patients with high grade glioma was 
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conducted by Taphoorn and Stupp et al, where same patients as in multicentre trial by 
the European Organisation for Research and Treatment of Cancer (EORTC) and the 
National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) were assessed 
for health related quality of life using standard EORTC questionnaires (QLQ-C30, 
version 3 and QLQ-BN20). Overall HRQOL score and individual scores were 
assessed, namely Fatigue, Future uncertainty, Social function, Emotional function, 
Insomnia and Communication deficit. These variables were assessed at different 
points before, during and after treatment. Overall HRQOL did not deteriorate by a 
clinically meaningful amount in all treatment groups over time after treatment, and 
even improved for some assessment times or scales. Moreover, the improving 
HRQOL scores over time was attributed to only the limited number of patients 
without recurrent disease, and thus the seeming improvement could be a result of so-
called survivorship.(6) 
 
Quality of life studies by Jalali et al has shown significant relationship with 
performance score, literacy, socioeconomic status and also the type of surgical 
intervention, where near-total or complete excision was associated with better 
outcomes.(41) Bosma et al, has shown that long-term survivors show improvement in 
HRQOL during the course of their disease and even attain levels that are comparable 
to that of healthy controls, whereas short-term survivors start at a lower level and 
hardly show improvement. However, in the long-term survivor group, tumour 
recurrence interfered with HRQOL, particularly with physical problems and feelings 
of future uncertainty.(36) 
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Disease recurrence has a significantly deleterious impact on patient life. Patients carry 
a significant symptom burden and neurological deficits are more severe at the time of 
recurrence than at initial presentation. Not surprisingly, the HRQOL of patients with 
tumour recurrence is more compromised than that of patients without recurrence after 
the same time since diagnosis.(36) 
 
EFFECT OF TREATMENT ON HEALTH RELATED QUALITY OF LIFE 
Effect of Surgery on HRQOL 
Apart from establishing a histologic diagnosis, the goal of glioma surgery is to resect 
as much tumour tissue as possible. Reduction in size of the tumour mass will reduce 
the neurological symptoms and cognitive deficits, thereby improving quality of life.  
 
At the same time, surgery as such and perioperative injuries may cause neurological 
and focal cognitive deficits as a result of damage to surrounding brain tissue. 
Although these deficits are transient, they may result in a temporarily lower perceived 
quality of life in most of the patients.(42) 
 
In a nonrandomized prospective study by Brown et al, it was noticed that patients who 
had gross total resection had both longer survival duration and a better HRQOL than 
patients who only had a biopsy. Moreover, the HRQOL of patients who had 
undergone gross-total resection increased over period of survival. Hence, it appears 
that the benefit of resection in terms of quality of life outweighs the early side effects 
of surgery.(39) 
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On the other hand, in a prospective study by Jakola et al which assessed HRQOL 
preoperatively and 6 weeks after surgery, it was observed to have a slight, non-
significant, overall decline in median HRQOL scores at the group level and at the 
individual patient level, 44%–49% of the patients reported deterioration in HRQOL 
postoperatively. Occipital lesions, postoperative ataxia, motor or language deficits, 
and lack of ultrasonography use for resection control were found to be associated with 
deterioration in postoperative HRQOL. Also, deterioration in HRQOL soon after 
surgery was found to be associated independently with poorer survival.(42) 
 
Effect of Radiotherapy on HRQOL 
There is not much evidence from randomised control trials to establish the actual 
effects of radiotherapy on high grade glioma patients with respect to quality of life. 
However, the volume of data for the same in low grade gliomas is essentially huge. 
The EORTC 22845 trial revealed that radiotherapy for low grade glioma will prolong 
progression-free survival and it could be hypothesized that, by postponing progressive 
tumour growth, patient functioning and thereby HRQOL would be preserved by 
radiotherapy. However, the EORTC 22844 trial has shown that apart from beneficial 
effects, radiotherapy may also have a negative impact on HRQOL in low grade glioma 
patients. Patients treated with high-dose radiation had a more compromised HRQOL 
following treatment than those received low-dose radiation, whereas overall survival 
did not differ between treatment arms. The immediate effects of radiotherapy, such as 
fatigue or symptoms of increased intracranial pressure, and long-term effects, such as 
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a decline in cognitive functioning resulting from irreversible radiation encephalopathy 
will consequently affect HRQOL in a negative way.(43) However, the results should 
be interpreted with caution with respect to high grade glioma and it cannot be 
extrapolated as such into the case of high grade glioma considering the variations in 
natural history of both diseases. 
 
In contrast to the findings in low grade glioma patients, benefit of radiotherapy is well 
established in the treatment of high grade glioma, because tumour progression is 
postponed and overall survival is extended. Hence by stabilizing disease and delaying 
progression, quality of life can be maintained. Randomized studies by Osoba et al and 
Taphroon et al, evaluating chemo-radiotherapy versus radiation therapy alone had 
included HRQOL as an outcome measure. Thus it was observed that radiotherapy had 
very minimal negative effects on quality of life in patients with anaplastic 
oligodendroglioma and glioblastoma. On longer follow-up, 1.5 years after the 
completion of radiotherapy, the HRQOL scores of high grade patients without 
progression even improved over their scores at the start of the treatment and in long-
term (i.e. 2 years from initial treatment) high grade glioma survivors without disease 
progression who had initial radiotherapy, HRQOL scores were observed to meet the 
level of healthy controls.(5,44) 
Effect of Chemotherapy on HRQOL 
Standard chemotherapy regimens in high grade glioma patients are the PCV regimen – 
(combination of Procarbazine, CCNU, and Vincristine) and Temozolomide. 
Compared with PCV, Temozolomide has the advantage of oral administration and less 
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bone marrow as well as subjective toxicity hence it is the gold standard currently. The 
combination of Temozolomide chemotherapy and radiotherapy led to a significantly 
longer survival in glioblastoma patients than in patients treated with radiotherapy 
alone.(45) 
 
The effect of this new dual-treatment modality on HRQOL was evaluated separately 
in some studies. The randomised trial by Taphroon et al has shown that different 
domains of quality of life improved with chemo-radiotherapy and the improvement 
was stable as long as there was no disease progression. However, during treatment, the 
patients in the combination treatment group reported more acute side effects (nausea, 
vomiting, appetite loss, and constipation) than those in the radiotherapy only group, 
which can be attributed to the use of Temozolomide and antiemetic. Overall, it was 
concluded that the addition of Temozolomide during and after radiotherapy produced 
a significantly longer survival without a long-lasting negative effect on HRQOL.(44) 
 
With respect to HRQOL, patients receiving PCV chemotherapy showed significantly 
more nausea/vomiting and appetite loss during and shortly following treatment than 
patients receiving only radiotherapy. Furthermore, patients on PCV reported more 
drowsiness. These differences, however, resolved over time: after 1 year of follow-up, 
differences were no longer observed in HRQOL between treatment groups. In a head 
on comparison between PCV regimen and Temozolomide by Stupp et al, patients 
receiving PCV regimen showed deterioration in most HRQOL domains during 
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treatment, whereas patients treated with Temozolomide improved while on 
treatment.(45,46) 
 
Addition of anti-VEGF agent Bevacizumab to chemo radiotherapy with respect to 
changes in health related quality of life was also assessed in some phase III trials but 
came out with conflicting evidences. Study by Chinot et al has shown an improvement 
in HRQOL with addition of Bevacizumab however the trial by Gilbert et al has shown 
deterioration in quality of life in Bevacizumab arm compared to non-Bevacizumab 
arm.(47,48) 
 
Effect of Supportive Treatment on HRQOL 
Symptomatic medications prescribed for glioma patients include antiepileptic drugs 
(AEDs) and steroids (Dexamethasone). In a study by Klein et al, the impact of 
seizures and AEDs on cognition and quality of life showed that both cognitive 
functions and HRQOL deteriorated in glioma patients mainly due to multiple episodes 
of seizures. Because the occurrence of seizures can diminish HRQOL, it could be 
assumed that treatment with AEDs improves quality of life. However, an adverse 
effect of AEDs on cognition has also been demonstrated in some studies. The 
cognitive deficits could primarily be ascribed to the use of AEDs, whereas the low 
HRQOL scores were mainly related to poor seizure control. Dexamethasone reduces 
peritumoural oedema and is prescribed to alleviate neurological symptoms, thereby 
improving quality of life. However, common side effects are myopathy, 
gastrointestinal complications, hyperglycaemia, and psychiatric complications (mainly 
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agitation or depression) can have a minimal negative impact on overall health related 
quality of life.(6) 
 
HEALTH RELATED QUALITY OF LIFE IN CLINICAL PRACTICE 
Mauer et al has shown that HRQOL parameters have independent prognostic role in 
various types of cancers including high grade gliomas. Two studies performed in 
HGG patients determined the prognostic significance of FACT scores. The study by 
Schen et al demonstrated that patients with high scores on the FACT-G had longer 
survival times than patients with low scores and using the FACT-Br in combination 
with a five-item linear analogue scale assessment, also found a relation between high 
HRQOL scores and longer survival on univariate analysis. However, Brown et al 
came with conflicting results and reported that HRQOL was closely related to 
functional status, and after correction for this in a multivariate analysis, no prognostic 
significance of HRQOL scores remained. Mauer et al did a classical analysis of 
EORTC QLQ-C30 sub scores, controlled for major prognostic factors such as age and 
performance status and identified cognitive functioning, global health status, and 
social functioning as statistically significant prognostic factors for survival in 
glioblastoma patients. In patients with anaplastic oligodendroglioma, emotional 
functioning, communication deficit, future uncertainty, and weakness of legs were 
found to be significant prognostic factors. From these analyses, it can be concluded 
that, although various HRQOL scales have prognostic value they have no additional 
value over already known clinical factors.(39,49) 
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However, in another aspect, HRQOL data may have value in daily clinical practice. 
Routine HRQOL measurements of oncology patients with information provided to 
physicians have been shown to have a positive effect on physician–patient 
communication. In some patients, these measurements improved HRQOL and 
emotional functioning. However, measurement of HRQOL, symptoms, and 
functioning is still far from being implemented in daily practice. In the future, a core 
set of standard and disease-specific questions repeated at key points in the disease 
trajectory (beginning of treatment, mid treatment, during follow-up, at relapse) should 
be implemented to allow comparison over time.  
 
NEUROCOGNITIVE FUNCTIONING 
By general definition, neurocognitive functions are functions closely linked 
toparticular areas, neural pathways or cortical networks in the brain substrate layers of 
neurological matrix at the cellular molecular level. It is closely related to the structure 
and function of the brain with respect to perception, defragmentation of concepts, 
memory, association and recall both in the thought process and behaviour. A 
neurocognitive deficit is an impairment of cognitive function in one of these areas, 
particularly when physical changes have occurred in the brain, such as after 
neurological illness, mental illness, drug use, or brain injury. Losing one’s personality, 
cognitive skills, and memory is a terrifying vision for everyone, yet it is a realistic 
imminent threat for patients living with malignant gliomas. 
The brain regulates indispensable “basic” functions for living such as breathing, 
sleeping and appetite as well as the primary sensory, perceptual, motor and autonomic 
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functions. Moreover, cognitive functions are extremely highly developed in human 
beings. These “higher” brain functions include attention, memory, producing and 
understanding language, learning, reasoning, problem solving, and decision making.  
 
Cognitive impairment including personality changes, social isolation, inability to run 
daily life and changes in behaviour are among the typical features of patients with 
high grade glioma leading to evaluation for brain tumour by imaging. Gliomas affect 
the architecture and function of the brain and consequently make impact on cognition 
in multiple ways. Not only the functions of the brain region where the tumour is 
located, but also the connections to and from this area are disturbed. Apart from 
oedema and intracranial pressure, seizures and also supportive drugs such as 
antiepileptic agents and corticosteroids potentially influence patients´ cognitive 
functions according to the study by Klein and Taphroon. Additionally, changes in 
sleep patterns or even stressors due to the imminent threat of cancer disease diagnosis 
may also affect the cognition of the patients. Thereby it is understandable that 
cognitive impairments are very common in patients with gliomas.(6,38) 
 
The outcome of cognitive abilities in patients with brain tumours and the effects of 
treatment on it have been studied extensively in all age groups; however significant 
data is available in paediatric age-groups and low grade gliomas mainly attributed to 
the long term survivorship in both groups. There are fewer data for patients with high-
grade gliomas and their cognitive outcomes with respect to different treatment 
modalities and in cases of disease recurrence.(50) 
51 
 
Neurocognitive functioning in high grade gliomas 
High grade gliomas cause profound changes in cognitive function thereby adversely 
affecting the personality, psychological well-being, and ability to perform daily 
activities. These changes negatively affect the productivity and independence of the 
patients, impacting their quality of life including social functioning, physical well-
being, social and financial status, and self-esteem (Sherer et al.,1997).(51) As a matter 
of fact, a better appreciation of the patterns of cognitive deficits and associated 
behavioural changes that can happen in high grade glioma patients can aid in the 
modification of current interventional strategies like the type of surgery, technique of 
radiotherapy, judicious use of steroids and antiepileptic drugs. It will eventually help 
to improve the cognition, quality of patient care, and ultimately improve the overall 
quality of life for high grade glioma patients and their families. Numerous studies 
have focussed on the decline in neurocognitive functions in high grade glioma patients 
whereas data is lacking on how to reduce and rehabilitate neurocognitive dysfunction 
early in the disease course.(52) Studies by Amiez et al have shown promising results 
with usage of functional MRI to monitor the neuropsychological domains and also 
using intra-operative neuropsychological assessment which can aid in preserving the 
neurocognitive functions.(53) 
Various factors contribute to the neurobehavioral changes associated with gliomas. 
Invariably high grade glioma patients have poorer outcomes compared to low grade 
gliomas. While manifestations of this disease vary substantially between patients, 
some general comments regarding tumour related and patient-related factors and their 
impact on cognition are warranted. 
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Location of tumour 
Laterality of the tumour is an important determining factor in the neurocognitive 
dysfunction associated with it. Left hemisphere tumours may produce language 
disorders that impair the patient’s ability to communicate with others and comprehend 
spoken or written language. Tumours in the right hemisphere may cause deficits in 
visual perception and visual scanning, resulting in impaired driving skills or the 
inability to navigate in familiar places. Memory loss is often seen in association with 
tumours of either hemisphere. Studies by Salo et al and Philip Hendrix et al showed 
that the detrimental effects of frontal tumours on neurocognition as compared to other 
lobes. Impairments of frontal lobe function such as executive deficits manifested by 
impairments of cognitive flexibility, abstraction, motivation, planning and 
organizational skills, ability to benefit from experience, personality changes, are 
ubiquitous in brain tumour patients. According to Salo et al, tumours in the right 
hemisphere and anteriorly located are associated with poorer outcomes.(54,55) 
Tumour volume is a strong predictor of certain neurocognitive deficits. Tumours with 
high volume result in poor performance in perceptual speed, executive function, 
memory and verbal fluency. Similar observations for deterioration of executive 
function and verbal fluency with increasing tumour volume have been made by the 
Volume of the tumour studies by Hendrix et al and Taphroon et al. Salo et al has 
demonstrated in one of his studies, volume of more than 25 ml is associated with 
poorer outcomes.(44,55) 
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Patient characteristics 
The age of the patient also contributes to the manifestation and severity of 
neurobehavioral deficits. For example, older patients tend to have more malignant 
brain tumours. Older patients are also at higher risk for having other concurrent 
neurodegenerative illnesses, such as Parkinson’s disease or vascular disease. Finally, 
older patients may be more sensitive to the toxic side effects of treatment.(11) 
 
Adverse effects of Surgery on neurocognitive functioning 
Systematic reports of the immediate and long-term surgical effects on cognition are 
rare. Available data have shown that surgery has a minimal negative effect on 
cognitive function among patients with high grade glioma.(6) These effects differ 
from those of diffuse cognitive disturbance caused by radiotherapy and chemotherapy. 
However, the extent of tumour removal has not been found to affect cognition. Studies 
by Kao and Chapman et al have reported that surgery-related perioperative 
complications are the dominant cause of post-operative cognitive deficits, including 
bacterial meningitis, neurological deficits, shunt infection, and multiple surgeries.(56) 
 
Adverse effects of Radiotherapy on neurocognitive functioning 
The damage from radiation treatments is generally evident several years following 
treatment and may be progressive and irreversible. The area of injury may present as 
an expanding mass of necrosis. Older patients, young children, and individuals who 
receive concomitant high-dose chemotherapy are at greatest risk for suffering from the 
adverse effects of radiation. Symptoms in adults generally include memory loss, gait 
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disturbance, weakness, and tremor. In children, general intellectual incapacity and 
severe learning disabilities may be seen following aggressive treatment. Irradiation 
causes injury to subcortical white matter, with larger treatment volumes causing more 
impairment. (6) 
 
Most studies that include neuropsychological assessment of brain tumour patients 
before and after radiation therapy reveal significant impairments of information-
processing speed, executive functions, memory, sustained attention, and motor 
coordination. These deficits are correlated with reduced cerebral blood flow seen on 
single-photon emission computed tomography imaging. Many studies have focused 
on memory deficits as the primary adverse effect of therapy in brain tumour 
patients.(57) 
Salander et al found that patient with high grade gliomas who were disease free and 
without neurologic deficits developed impairments of verbal learning and memory but 
did not differ from their spouses on tests of verbal comprehension, visuospatial skills, 
or abstract reasoning 5 months after their initial treatment. Archibald et al found that 
memory and concentration tended to be most impaired 18 months after treatment, with 
further declines in frontal lobe executive functions and new learning ability during the 
ensuing 2 years.(58) 
 
Kleinberg et al reported, in contrast, that 65% of their glioma patients had only mild 
memory deficits that did not prevent them from returning to work. The 
neuropsychological effects of treatment do not correlate with the appearance of white 
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matter changes on neuroimaging, although the development of white matter changes is 
closely correlated with radiation dose. This is due to both the resolution of anatomic 
changes on MRI and the fact that many changes in brain function are caused by 
biochemical alterations that occur before structural abnormalities may be 
visualized.(59) 
Lawrence et al has done a systematic review on effects of radiation dose on 
neurocognitive functioning. The study has found that neurocognitive impairment 
happens in children with doses >18Gy in conventional fractionation and in adults, 
there was no substantial evidence to comment on irreversible neurocognitive 
dysfunction due to partial brain conventional fractionated radiotherapy. Whole brain 
radiotherapy and hypo fractionated regimes were found to be more detrimental.(60) 
 
Adverse effects of Chemotherapy on neurocognitive functioning 
Although cognitive changes following chemotherapy have been well documented, 
there have been very few prospective studies investigating the long-term effects of 
chemotherapeutic agents on cognition. Most of the published data is on concurrent 
chemo-irradiation. A small single institution study by Hilverda and Bosma et al have 
shown, cognitive decline in three out of 13 progression-free patients after concurrent 
chemo-irradiation and three cycles of adjuvant chemotherapy with standard-dose 
Temozolomide.(61,62)  Declines were evident in psychomotor speed, attention and 
executive function, but not in verbal memory or working memory span. The results of 
a larger multi-institutional cooperative group trial by Armstrong et al, comparing 
adjuvant standard-dose Temozolomide and dose-dense Temozolomide have also 
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reported cognitive decline in 30% patients with no differences between arms. 
Cognitive decline was evident in all domains assessed including verbal learning and 
memory, executive function and processing speed – and was prognostic of 
progression-free and overall survival.(63) 
Adverse Effects of Adjunctive Medications 
Steroids: 
Glucocorticoid treatment for mass effect and raised intracranial pressure is ubiquitous 
among brain tumour patients. However, steroids may also have adverse effects on 
mental and emotional functioning.(6) Lewis and Smith et al showed that the incidence 
of steroid-induced psychiatric syndromes ranged from 5.7% to 50%. These side 
effects include euphoria, mania, insomnia, restlessness, and increased motor activity. 
Some patients become anxious and depressed. Steroids are also known to have 
adverse effects on memory, even in normal control subjects. Treatment with 
glucocorticoids may also potentiate the neurotoxic side effects of other agents.(64) 
 
Anticonvulsants: 
For many patients, seizures are the initial symptom of brain tumour. The overall 
incidence of epilepsy among brain tumour patients is estimated to be 35%. When the 
dosages of anticonvulsant drugs such as Levetiracetam, Phenytoin and Carbamazepine 
are carefully monitored, their cognitive effects are minimal. Use of phenobarbital, 
however, has been associated with greater adverse cognitive effects. Regardless of the 
specific medication used, too rapid an introduction of the anticonvulsant, 
polypharmacy, or excessive doses may result in changes in arousal, attention, 
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memory, and psychomotor functioning. It should be noted, however, that the majority 
of children and adults who take these drugs experience few side effects.(6) 
 
Additionally, changes in sleeping pattern or even grief reaction due to the imminent 
threat of a serious cancer disease may affect the cognition of the patients. Thereby it is 
understandable that cognitive impairments are very common in patients with gliomas.  
Tucha and colleagues found cognitive disturbances before treatment, including 
surgery, in 126 of 139 patients (91%) with different brain tumours. However, most 
deficits disappear at least transiently after removal of compressive tumours by 
surgery. Recent studies show, that cognitive dysfunctions are not restricted just to the 
brain area where the tumour is located or removed. Glioblastoma with infiltrative 
features leads to different types of general cognitive impairments, such as 
concentration problems or difficulties with planning, which cannot be confined just in 
distinct brain regions. Several studies showed the relevance of changes in cognition as 
parameter for radiotherapy side effects, for perceived quality of life and its prognostic 
value in brain tumour patients.(50) 
 
Meyers et al showed that cognitive deterioration is an important sign indicating 
disease recurrence in patients with Glioblastoma even before radiological features of 
recurrence are detectable. In addition, Taphoorn and Klein concluded in their study 
that cognitive decline might be the first indicator of tumour regrowth. Nevertheless, 
when measuring and analysing cognitive functions of brain tumour patients, one has 
to be aware of dealing with a situation, where usually no baseline cognition-
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assessment is available for comparison. However, high scores in cognition shortly 
after diagnosis, together with the clinical components, young age and high 
performance scales are among the prognostic factors for longer survival.(59,65) 
MATERIALS AND METHODS 
A prospective observational study was done from March 2017 to August 2017 at 
Christian Medical College, Vellore to assess Health Related Quality of Life (HRQOL) 
and Neurocognitive Function in patients with high grade glioma willing for adjuvant 
treatment. 
Study Design: 
This hospital based observational prospective study was conducted on outpatients 
diagnosed with high grade glioma who underwent surgical excision and willing for 
adjuvant treatment with concurrent chemo-irradiation and adjuvant chemotherapy, in 
whom patient reported HRQOL and NCF assessment studies were done at three time 
points, namely, before starting concurrent chemo-irradiation, after concurrent chemo-
irradiation and after completion of adjuvant chemotherapy. The study was approved 
by the IRB Ethics committee (BLUE IRB Min No: 10489).  
Setting: 
The study was conducted in the Outpatient department of Radiation Oncology, RT 
Block of Christian Medical College Vellore from March to August 2017. 
Participants: 
All patients above 18 years of age diagnosed with grade 3 or 4 glioma, who attended 
Radiation Oncology department for adjuvant treatment with chemo-radiotherapy.  
Inclusion criteria– 
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1. Patients with high grade glioma who received  post op radiotherapy with 
concurrent and adjuvant Temozolomide 
2. Age: 18 – 70 years  
3. Karnofsky Performance Score >60 
4. Patients who can read and understand English/Hindi and consented for the 
study 
Exclusion criteria – 
1. Recurrent glioma  
2. Re-irradiation  
3. History of treatment for any other malignancies other than carcinoma cervix in 
situ and skin cancers 
4. Aphasic patients  
Methodology: 
All patients with high grade glioma who attended Radiation Oncology department for 
adjuvant treatment during the time period of study were screened and those who met 
the inclusion criteria and consented for the study were recruited for the study.  
All patients received radiotherapy to the tumour bed with concurrent and adjuvant 
chemotherapy based on the Stupp regime. Patients’ demographic characteristics, type 
of surgery, location of the tumour, final histopathology including 
immunophenotyping, postoperative complications, and details of medication were 
collected. First assessment of HRQOL and NCF was done prior to starting 
radiotherapy.  
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Treatment protocol: 
Radiotherapy – 
Adjuvant radiotherapy was started after a short post-operative recovery phase and 
wound healing. Radiotherapy was delivered using gamma rays from Telecobalt 
machine with conventional technique or with photons from a Linear Accelerator using 
conformal technique. 
Conventional Radiotherapy technique: 
All the patients for conventional treatment were simulated in a X-ray Simulator 
(Varian Ximatron). Patients were positioned supine and head immobilised with POCL 
head support and thermoplastic ray cast. Parallel opposed lateral fields were used with 
the dose prescription to the midplane.  The eyes or normal brain outside the PTV were 
shielded with lead blocks.  The conventional radiotherapy was delivered in two phases 
as per RTOG protocol. For Phase I, the resection cavity with residual tumour and 
surrounding oedema as in T2 FLAIR MR Image was given a margin of 2 cm and field 
edges were fixed. For Phase 2, the residual contrast enhancing tumour with resection 
cavity as in T1 contrast MR image was given a margin of 2 cm.  
Conformal Radiotherapy technique: 
Patients who have opted for conformal treatment were simulated in a CT simulator 
(Siemens Biograph) in supine position and immobilisation with Head support and 
thermoplastic ray cast with three reference points marked on the mask. Planning CT 
with Contrast was taken from vertex to upper border of C4 with a slice thickness of 3 
mm. This CT scan was fused with volumetric protocol MRI scan – T1 GADO and T2 
FLAIR sequences. The contouring was done on Varian Eclipse Treatment Planning 
System. In conformal technique also, treatment was planned in two phases, according 
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to the RTOG protocol. Phase I GTV was the resection cavity with the residual tumour 
and perilesional oedema, contoured from T2 FLAIR images fused with planning CT 
scan. The CTV was 1.5 cm margin to the surrounding brain. The CTV margin was 
reduced to 0.5 cm across the falx and into the ventricles.   
For Phase 2, the GTV was the surgical resection cavity with residual tumour, 
contoured on T1 Gadolinium MRI images fused with planning CT. The GTV to CTV 
expansion was similar to phase I volume.   PTV margin of 3mm was given for phase I 
and phase II CTVs. The organs at risk contoured were bilateral eyes and optic nerves, 
optic chiasm and brain stem. 
Radiotherapy doses: 
Glioblastoma: 
Phase I – 46Gy in 23 fractions, 5 days a week, 2Gy per fraction  
Phase II – 14Gy in 7 fractions, 5 days a week, 2Gy per fraction  
Grade 3 gliomas: 
Phase I - 45Gy in 25 fractions, 5 days a week, 1.8Gy per fraction. 
Phase II –14.4Gy in 8 fractions, 5 days a week, 1.8Gy per fraction.  
Chemotherapy: 
Concurrent and adjuvant chemotherapy with Temozolomide was based on the Stupp 
et al regimen. Adjuvant chemotherapy was started four weeks after completion of 
concurrent chemo-irradiation. 
Concurrent chemotherapy dose of Temozolomide was 75mg/m2, administered on all 
days during the course of radiotherapy after 4 hours of fasting and anti-emetic 
medications.  All patients were clinically assessed weekly and blood tests including 
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complete blood count, renal and liver functions were monitored weekly while on 
concurrent chemotherapy. All patients were started on oral low dose steroids 
(Dexamethasone 1mg twice daily), Pyridoxine 50 mg once daily, Trimethoprim - 
sulfamethoxazole prophylaxis for pneumocystis pneumonia and continued on regular 
medication including antiepileptic drugs. After completion of concurrent chemo-
irradiation, patients had reassessment with HRQOL and NCF. Adjuvant dose of 
Temozolomide was150mg/m2, Days 1-5, for cycle 1 and 200mg/m2, Days 1-5, 
repeated every 28 days from Day 1 of the cycle, for cycles 2 to 6. 
 
 The HRQOL and NCF status was done at first follow up after adjuvant 
chemotherapy. MRI brain with Gadolinium was done at the end of adjuvant 
chemotherapy and for some patients who were symptomatic MRI brain was done 
earlier. In our study health related quality of life was assessed by NCCN FACT-Br 
(Version 4) and Neurocognitive function was assessed by both Mini Mental Status 
Examination and Montreal Cognitive Assessment (MOCA). 
Functional Assessment of Cancer Therapy-Brain (FACT-Br Version 4): 
FACT-Br is a commonly used questionnaire to assess the patient reported quality of 
life associated with brain tumours. It has been validated for clinical use after detailed 
psychometric evaluation. The questionnaire spans over 5 major domains, namely 
physical well-being, social/family well-being, emotional well-being, functional well-
being and disease specific concerns. Patients rate all the aforementioned 5 dimensions 
using a five-point Likert scale ranging from 0 "not at all" to 4 "very much." Overall, 
higher ratings suggest higher QOL. It is written at the 4th grade reading level and 
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patients can do the entire questionnaire in 5-10 minutes without any assistance. Some 
of the questions in FACT-Br questionnaire required reverse scoring and hence 
negative scores were given for the same. (Annexure 3A) 
Mini Mental State Examination (MMSE): 
The Mini Mental State Examination is a reliable validated questionnaire which can be 
used as a screening test for assessing the cognitive functioning of patients with 
suspected neuropsychiatric impairment. It has a total of 11 questions and maximum 
score of 30. It has two sections, the first of which requires vocal responses only and 
covers orientation, memory, and attention. The second part tests ability to name, 
follow verbal and written commands, write a sentence spontaneously, and copy a 
complex polygon similar to figures used in the Bender Visual Motor Gestalt Test/ 
Bender-Gestalt Test (BGT). The following three cut-off levels are employed to 
classify the severity of cognitive impairment: no impairment = 24-30; mild 
impairment = 18-23; severe impairment = 0-17. (Annexure 3C) 
Montreal Cognitive Assessment (MOCA Version 7.1): 
MOCA is a screening instrument with high sensitivity and specificity for detection of 
cognitive impairment. It evaluates seven cognitive domains and scores range from 0 to 
30. The domains are: visuospatial/executive functions, naming, verbal memory 
registration and learning, attention, abstraction, 5-minute delayed verbal memory, and 
orientation. (Annexure 3B) 
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Patients with high grade glioma who were willing to 
have adjuvant treatment at CMC, Vellore from April 
to August 2017 
The patients who met with inclusion criteria and 
consented were recruited for study 
HRQOL and NCF assessment before starting 
radiotherapy using FACT Br, MOCA and MMSE 
questionnaires 
Adjuvant Radiotherapy with concurrent Temozolomide 
as detailed above 
HRQOL and NCF assessment after completion of 
chemo-radiotherapy using FACT Br, MOCA and 
MMSE questionnaires 
 
Adjuvant chemotherapy with Temozolomide for 6 
months 
HRQOL and NCF assessment after completion of 
adjuvant chemotherapy using FACT Br, MOCA and 
MMSE questionnaires& 
MRI Brain for disease status assessment at end of 
completion of adjuvant chemotherapy 
 
 
Lost to follow up 
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Sample size: 
With a clinically important difference of 3–7 points established in the proposed 
questionnaire and with a standard deviation of 3, the calculated sample size was 10 
patients. Considering 30% attrition, estimated sample size was 13 patients. The entire 
sample size calculation was done for 5% error and 80% power. 
 
Where, 
µ1 = Mean of pre score 
µ2 = Mean with post score 
σ1 = Standard deviation of pre score 
σ2 = Standard deviation of post score 
 
Statistical Methods: 
All the quantitative variables were summarized using mean with Standard Deviation 
(SD) or median with Inter quartile range (IQR) depending on the distribution of each 
of the variable and categorical data will be summarized using frequency and 
percentage. The comparison of outcome for each quantitative variable was done using 
paired t-test or sign rank test.  Pearson correlation/Spearman's rank correlation was 
used to detect the relation between questionnaire and demographic variables. The 
relation between questionnaire scores and categorical demographic variables were 
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analysed using independent t-test or ANOVA test. All the statistical analysis was done 
using STATA IC/15.0 software. 
Results 
All patients presented to Department of Radiation Oncology for adjuvant therapy 
between March 2018 and August 2018 was screened for eligibility to the inclusion 
into study. Out of the 46 patients screened during the time period, 20 patients who met 
the inclusion criteria were recruited.   
Patient characteristics: 
Patients’ age ranged from 18 to 67 years with median age of 42 years. Out of 20, 15 
(75%) were male and 5(25%) were female patients. The performance stat u was KPS 
90 in 17(85%) patients, 80 in one patient (5%) and 70 in two patients (10%) (Table 1). 
Table 1: Baseline patient characteristics 
Unique ID No Age in years Gender KPS Education 
1 48 Male 70 Graduate 
2 27 Male 70 Graduate 
3 60 Male 90 12th grade 
4 60 Female 90 12th grade 
5 67 Female 90 12th grade 
6 42 Male 90 Graduate 
7 27 Male 90 12th grade 
8 37 Male 90 Graduate 
9 23 Male 90 Graduate 
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10 47 Male 90 12th grade 
11 27 Female 90 Graduate 
12 42 Male 90 12th grade 
13 40 Male 90 12th grade 
14 27 Male 90 Graduate 
15 48 Male 90 Graduate 
16 54 Female 90 Graduate 
17 49 Male 80 12th grade 
18 43 Male 90 Graduate 
19 18 Male 90 12th grade 
20 38 Female 90 12th grade 
 
Disease characteristics: 
Out of the 20 recruited patients, 50% (10) were diagnosed to have Glioblastoma, 40% 
(8) Anaplastic astrocytoma and 10% (2) Anaplastic oligodendroglioma (Figure 16). 
Figure 16: Histology 
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Further characterisation of molecular biology was done with markers such as p53, 
MGMT mutation, IDH-1 mutation, 1p19q co-deletion and ATRX expression. P53 was 
checked in all patients and 90% of the patients (18 patients) had positive mutation. Of 
the eight patients in whom MGMT mutation analysis was done, all were found to be 
MGMT promotor methylation positive. IDH-1 mutation status was checked in all 
patients and 60% (12) were found to have the mutation. Of the 14 patients analysed 
for ATRX expression, 50% (7) had retained ATRX expression. 1p19q co-deletion was 
present in 40% (2 patients) of the 5 patients subjected for testing and both were 
anaplastic oligodendroglioma (Figure 17). 
Figure 17: Molecular characteristics
 
 
 
 
Tumour location and characteristics: 
Tumour was located on right side of cerebral hemisphere for 11(55%) patients and on 
left side for 9 (45%) patients. Most common location was noted to be Frontal lobe 
(35%) followed by Parietal lobe (30%) (Figure 18). 
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Figure 18: Tumour Location 
 
 
Presenting symptoms: 
Most common presenting symptom was headache and vomiting which was present in 
70% (14) of the patients. Seizure was the presenting symptom in 60% patients. Other 
symptoms include altered sensorium, neurological or cognitive deficits, vertigo, and 
bowel/bladder incontinence (Figure 19). 
Figure 19: Presenting symptoms 
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Details of surgery: 
All the patients had maximal safe resection of tumour which is the current standard of 
care. Subtotal resection was done in 50% (10) of the patients, gross tumour resection 
in 45% (9) and frontal lobectomy in one patient (5%) (Figure 20). All the patients had 
MRI Brain in the immediate post-operative period to assess the extent of surgery and 
evidence of injury to normal brain parenchyma. None of the patients were subjected to 
re-exploration surgery. Of the 20 patients, only 2 had post-operative pseudo-
meningocoele and both patients were managed conservatively. No patient had post-
operative infection. However, 4 patients (20%) recruited new motor or sensory 
deficits and 2 patients (10%) developed neurocognitive dysfunction post-operatively 
(Figure 21). 
Figure 20: Details of surgery 
 
Figure 21:Post-operative complications: 
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Gap between Surgery and adjuvant treatment: 
The median gap between surgery and starting radiotherapy was 17 days (12–31 days). 
Six patients (30%) started radiotherapy within two weeks of surgery, whereas four 
patients (20%) started radiotherapy after four weeks. Rest of the patients (50%) were 
started within three weeks from the date of surgery. The delay in starting radiotherapy 
was due to personal reasons (Figure 22). 
Figure 22: Gap between surgery and radiotherapy 
 
Details of chemo-radiotherapy: 
All the patients received concurrent chemo-radiotherapy with Temozolomide based 
Stupp regimen. The technique of delivering radiation therapy was Conventional using 
Telecobalt in 90% (18) of the patients and 3D conformal technique in Lineal 
Accelerator in 10% (2) patients (Figure 23). 
Figure 23: RT Technique 
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Radiotherapy Doses: 
The median radiotherapy dose was 5940cGy (range 5580–6000cGy) with 180-200cGy 
per day in 28-33 fractions. Of the Glioblastoma patients, 9(45%) received 6000cGy in 
30 fractions and 1(5%) received 5600cGy in 28 fractions. Among the Anaplastic 
astrocytoma and oligodendroglioma, 3(15%) patients received 5940cGy in 33 
fractions and 5 patients (25%) received 5580cGy in 31 fractions and 2(10%) received 
5600cGy in 28 fractions. The total dose was reduced in view of close proximity to 
brainstem in 3 patients. None of the patients developed grade 3 or 4 toxicity or 
required any break in radiotherapy (Figure 24). 
Figure 24: RT doses and fractionation 
 
 
Chemotherapy: 
All patients received concurrent chemotherapy with Temozolomide (75mg/m2) and 
the treatment was tolerated well with no grade 3/4 toxicity. However, two patients did 
not receive adjuvant chemotherapy due to personal reasons and of which one patient 
did not come for follow up (Figure 25). 
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Figure 25: Chemotherapy details 
 
Effect Modifiers during adjuvant therapy: 
All the patients received low dose Dexamethasone 1 mg twice daily which was 
gradually tapered and stopped after treatment. All the regular medications including 
anti-epileptic drugs were continued during the course of adjuvant therapy. All the 
patients (100%) were on anti-epileptic drugs and most commonly on Leviteracetam 
(Figure 26). 
Figure 26: Effect modifiers 
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Follow up: 
Out of the twenty patients recruited for study, 19 patients came for follow up after 
completion of chemo-irradiation and after completion of adjuvant chemotherapy (only 
18 patients completed adjuvant chemotherapy). The median follow up duration was 10 
months (range 6-16 months). One patient was lost to follow up after completion of 
concurrent chemo-radiotherapy and he did not take adjuvant chemotherapy. However, 
he was telephonically contacted regularly and has done the questionnaires at the 
appropriate time. The median progression free survival was 10 months (range 8–16 
months). Four patients (20%) were found to have disease recurrence (UID 1, UID 3, 
UID 5 and UID 15). 
Questionnaire response rate: 
The HRQOL and NCF assessment were done with the three questionnaires mentioned 
earlier, namely FACT-Br, MMSE and MOCA, independently at three time points. The 
questionnaire response was 100% at all the time points (Figure 27). 
 
Figure 27: Questionnaire response 
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Health related quality of life changes: 
The HRQOL scores at each point are mentioned in the tables below:- 
 
Table 2: Baseline HRQOL: 
QOL Parameter Mean Score Standard Deviation 
Physical well-being -20.95 2.012 
Social well-being 22.90 2.149 
Emotional well-being -12.75 2.149 
Functional well-being 9.35 2.601 
Additional concerns -17.30 8.868 
 
 
Table 3: HRQOLvariations post-radiotherapy and post-chemotherapy: 
QOL Parameter Post Radiotherapy Post Chemotherapy 
 Mean Score SD Mean Score SD 
Physical well-being -16.70 2.515 -10.75 5.460 
Social well-being 23.45 1.571 24.10 0.912 
Emotional well-being -8.70 1.976 -6.70 4.426 
Functional well-being 13.30 2.038 17.10 4.843 
Additional concerns -2.75 7.614 1.60 13.628 
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Changes in Physical well-being: 
Physical well-being score is a reflection of fatigue, nausea, pain, and side effects 
related to treatment. It was noted to have a statistically significant improvement in 
physical well-being over the time period of study between post-surgery and adjuvant 
therapy with a p value < 0.001. Only one patient (UID 1) was noted to have a gradual 
decline in the physical well-being score (Table 4). The mean score and standard 
deviation is mentioned in Tables 2 and 3. Variation in the score over the three 
specified time points was evaluated using the ANOVA test. The results are shown in 
the Table 5. The contrast in scores, i.e. the mean difference in scores between the 
different time periods was 4.25 in 1st v/s 2nd, 5.95 in 2nd v/s 3rd and 10.2 in 1st v/s 3rd 
(Figure 28). 
Table 4: Physical well-being score of patients with recurrence 
UID Number Pre Radiotherapy Post Radiotherapy Post Adjuvant 
Chemotherapy 
UID 1 -22 -19 -27 
UID 3 -21 -16 -9 
UID 5 -22 -21 -19 
UID 15 -24 -17 -22 
 
 
Table 5: Pairwise comparisons over the three time points: 
Time points Contrast in 
scores (ANOVA) 
p Value Unadjusted 95% confidence 
interval 
1st v/s 2nd 4.25 0.000 2.22 6.28 
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2nd v/s 3rd 5.95 0.017 3.92 7.98 
1st v/s 3rd 10.20 0.000 8.17 12.23 
 
Figure 28: Variations in Physical well-being score 
 
Changes in social well-being: 
Social well-being parameter is a marker of the emotional and social support patient 
gets from the family and friends. It was noted to have a statistically significant 
improvement in social well-being over the different time points of assessment with a p 
value <0.007 (Figure 29). None of the patients reported a decline in the value of 
support that they get from family and friends during the course of treatment which 
adds to improve their overall quality of life (Table 6). ANOVA test was used to 
compare the changes in social well-being scores over the three specified time points 
and the results are depicted in Table 7. The contrast in scores between 1st v/s 2nd time 
points was 0.55 and the corresponding p value was < 0.134 suggesting no statistical 
significance, whereas the overall social well-being score was high compared to other 
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parameters. The contrast in score between 2nd v/s 3rd and 1st v/s 3rd was 0.65 and 1.20 
with statistical significance as shown in the Table 7. 
Table 6: Social well-being score in patients with recurrence 
UID Number Pre Radiotherapy Post Radiotherapy Post Adjuvant 
Chemotherapy 
UID 1 17 17 23 
UID 3 6 11 15 
UID 5 8 12 9 
UID 15 13 16 21 
 
Table 7: Pair wise comparison over three time points: 
Time points Contrast in 
scores (ANOVA) 
p Value Unadjusted 95% confidence 
interval 
1st v/s 2nd 0.55 0.134 -0.18 1.28 
2nd v/s 3rd 0.65 0.078 -0.08 1.38 
1st v/s 3rd 1.20 0.002 0.47 1.93 
 
Figure 29: Variations in Social well-being score 
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Changes in emotional well-being: 
Emotional well-being is a marker of patient’s hope, nervousness, and fear of disease 
progression or death. There was statistically significant improvement in emotional 
well-being over the time period of study with a p value < 0.001 (Figure 30). Three 
patients, namely UID 1, UID 5 and UID 15 had decline in the emotional well-being 
(Score mentioned in Table 8), which can be attributed to the fact they had recurrence 
of disease. Despite the recurrence of disease, UID 3 showed an improvement in 
emotional well-being score. The contrast in scores between the three specified time 
points is shown in Table 9. Using ANOVA test, the contrast in score is 4.05 between 
1st v/s 2nd, 2.00 between 2nd v/s 3rd and 6.05 between 1st v/s 3rd. 
Table 8: Emotional well-being score of patients with recurrence 
UID Number Pre Radiotherapy Post Radiotherapy Post Adjuvant 
chemotherapy 
UID 1 -12 -8 -20 
UID 3 -15 -11 -7 
UID 5 -15 -10 -14 
UID 15 -14 -11 -14 
 
Table 9: Pair wise comparison over three time points: 
Time points Contrast in 
scores (ANOVA) 
p Value Unadjusted 95% 
confidence interval 
1st v/s 2nd 4.05 0.000 2.42 5.68 
2nd v/s 3rd 2.00 0.017 0.37 3.63 
1st v/s 3rd 6.05 0.000 4.42 7.68 
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Figure 30: Variations in Emotional well-being score 
 
 
Changes in functional well-being: 
Functional well-being characterised by enjoying life, accepting illness, getting 
involved in activities, sleep and quality of life. Our study has shown a statistically 
significant improvement in functional well-being with a significant p value < 0.000 
(Figure 31). However it was noted to have decline in functional well-being of two 
patients, namely UID 1, UID 5, and no improvement in one patient, UID 15, over the 
specified time period (Scores mentioned in Table 10). On the other hand, UID 3 
despite recurrence of disease showed a marginal improvement in functional well-
being score. The contrast in scores between three time points using ANOVA test is 
mentioned in the Table 11. It is clear that the difference in score was 3.95, 3.80 and 
7.75 in the time periods, 1st v/s 2nd, 2nd v/s 3rd and 1st v/s 3rd respectively. 
Table 10: Functional well-being score in patients with recurrence 
UID Number Pre Radiotherapy Post Radiotherapy Post Adjuvant 
chemotherapy 
UID 1 4 10 3 
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UID 3 6 11 15 
UID 5 8 12 9 
UID 15 7 11 10 
 
Table 11: Pair wise comparison over three time points: 
Time points Contrast in 
scores (ANOVA) 
p Value Unadjusted 95% 
confidence interval 
1st v/s 2nd 3.95 0.000 2.50 5.39 
2nd v/s 3rd 3.80 0.000 2.35 5.24 
1st v/s 3rd 7.75 0.000 6.30 9.19 
 
 
Figure 31: Variations in Functional well-being score 
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Changes in the additional concerns (General well-being): 
Additional concerns which were evaluated based on the questionnaire include fear of 
seizures, headache, memory, comprehension, vision, hearing, and skilled activity. 
There was statistically significant improvement over the period of time with a p value 
< 0.001 (Figure 32). Four patients, namely, UID 1,UID 3,UID 5,UID 15 who had 
decline in the score can be attributed to the disease recurrence (Scores are mentioned 
in the Table 12) The contrast in scores between the specified time points is, 14.55 in 
1st v/s 2nd, 4.35 in 2nd v/s 3rd and 18.90 in 1st v/s 3rd. The detailed results are shown in 
Table 13. 
Table 12: Additional concerns score in patients with recurrence 
UID Number Pre Radiotherapy Post Radiotherapy Post Adjuvant 
chemotherapy 
UID 1 -30 -16 -36 
UID 3 -33 12 -1 
UID 5 -23 -11 -21 
UID 15 -20 -4 -24 
 
Table 13: Pair wise comparison over three time points: 
Time points Contrast in 
scores (ANOVA) 
p Value Unadjusted 95% confidence 
interval 
1st v/s 2nd 14.55 0.000 9.46 19.63 
2nd v/s 3rd 4.35 0.091 -0.73 9.43 
1st v/s 3rd 18.90 0.000 13.81 23.98 
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Figure 32: Variations in Additional concerns (general) well-being score 
 
Changes in Global HRQOL: 
Global HRQOL refers to the sum of all the HRQOL scores over the three time points. 
As predicted by the individual health scores mentioned above, the global score also 
showed a similar trend with progressive improvement (p<0.001) in overall Quality of 
Life (Figure 33). Mean global quality of life scores and standard deviation is 
mentioned in Table 14. The contrast in scores between three specified time points is 
shown in Table 15. It is evident that the contrast in scores improved over the time 
period of study with statistical significance. Using ANOVA test, the contrast in score 
was 28.55 in 1st v/s 2nd, 15.55 in 2nd v/s 3rd and 44.10 in 1st v/s 3rd. 
Table 14: Mean Global HRQOL Score 
MEAN GLOBAL HRQOL SCORE 
Pre Radiotherapy Post Radiotherapy Post Chemotherapy 
Mean Score SD Mean Score SD Mean Score SD 
-18.75 14.495 9.80 10.792 25.35 28.303 
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Table 15: Pair wise comparison over three time points using ANOVA: 
Time points Contrast in scores 
(ANOVA) 
p Value Unadjusted 95% 
confidence interval 
1st v/s 2nd 28.55 0.000 19.63 37.47 
2nd v/s 3rd 15.55 0.001 6.63 24.47 
1st v/s 3rd 44.10 0.000 35.18 53.02 
 
Figure 33: Variations in Global HRQOL well-being score 
 
Changes in Neurocognitive functions: 
Neurocognitive functioning was assessed with two questionnaires as mentioned 
earlier, namely MOCA and MMSE at three time points, along with the HRQOL 
assessment.  
Changes in MOCA scores: 
There was a statistically significant improvement in neurocognitive functioning over 
the time period with a significant p value<0.001 (Figure 34). However, there was 
decline in the neurocognitive status of 3 patients namely, UID 1, UID 5 and UID 
15who were found to have disease recurrence, and one patient, UID 3, had no 
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improvement in scores which is mentioned in the Table 16. The Mean score with 
standard deviation and contrast in scores between the three specified time points is 
shown in Table 17.  Using ANOVA test, the contrast in score is 2.70 between 1st v/s 
2nd, 4.00 between 2nd v/s 3rd and 6.70 between 1st v/s 3rd (Table 18). 
Table 16: Decline in the MOCA score 
UID Number Pre Radiotherapy Post Radiotherapy Post Adjuvant 
chemotherapy 
UID 1 10 15 6 
UID 3 8 12 12 
UID 5 10 12 9 
UID 15 4 4 3 
 
Table 17: Mean MOCA Score 
MEAN MOCA SCORE 
Pre Radiotherapy Post Radiotherapy Post Chemotherapy 
Mean Score SD Mean Score SD Mean Score SD 
10.5 4.784 13.2 4.8731 17.2 5.916 
 
Table 18: Pair wise comparison over three time points using ANOVA: 
Time points Contrast in 
scores (ANOVA) 
p Value Unadjusted 95% confidence 
interval 
1st v/s 2nd 2.70 0.006 0.83 4.57 
2nd v/s 3rd 4.00 0.000 2.13 5.87 
1st v/s 3rd 6.70 0.000 4.83 8.57 
 
86 
 
Figure 34: Variations in MOCA score 
 
Changes in MMSE score: 
Similar to the assessment done with MOCA scale, there was statistically significant 
improvement in the neurocognitive function status (p < 0.000) based on MMSE as 
well (Figure 35). The Four patients, namely UID1, UID3, UID5, UID 15, who were 
noted to have no improvement in neurocognitive functioning with MOCA showed 
similar response with MMSE (Scores mentioned in Table 19). Mean score with 
standard deviation and contrast in scores between the three specified times points is 
shown in Table 20. Using ANOVA test, the contrast in score is 2.95 between 1st v/s 
2nd, 5.15 between 2nd v/s 3rd and 8.10 between 1st v/s 3rd (Table 21). 
Table 19: Decline in the MMSE score 
UID Number Pre Radiotherapy Post Radiotherapy Post Adjuvant 
chemotherapy 
UID 1 8 17 7 
UID 3 7 4 12 
UID 5 10 13 10 
UID 15 5 5 3 
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Table 20:  Mean MMSE Score 
MEAN MMSE SCORE 
Pre Radiotherapy Post Radiotherapy Post Chemotherapy 
Mean Score SD Mean Score SD Mean Score SD 
10.85 4.475 13.8 5.064 18.95 6.962 
 
 
Table 21: Pair wise comparison over three time points using ANOVA: 
Time points Contrast in 
scores (ANOVA) 
p Value Unadjusted 95% confidence 
interval 
1st v/s 2nd 2.95 0.009 0.77 5.12 
2nd v/s 3rd 5.15 0.000 2.98 7.32 
1st v/s 3rd 8.10 0.000 5.93 10.27 
 
 
Figure 35: Variations in MMSE score 
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Changes in Total Neurocognitive function score: 
Total neurocognitive function score is the sum of MOCA and MMSE scores. The 
results are in concordance with the individual score as explained earlier. 
Table 22: Total NCF Score 
TOTAL NEUROCOGNITIVE SCORE 
Pre Radiotherapy Post Radiotherapy Post Chemotherapy 
Mean Score SD Mean Score SD Mean Score SD 
21.35 4.475 27.00 9.851 35.05 13.020 
 
Table 23: Pair wise comparison over three time points using ANOVA: 
Time points Contrast in 
scores (ANOVA) 
p Value Unadjusted 95% confidence 
interval 
1st v/s 2nd 5.65 0.006 1.69 9.61 
2nd v/s 3rd 8.05 0.000 4.09 12.01 
1st v/s 3rd 13.7 0.000 9.74 17.66 
 
Figure 36: Variations in Total NCF score 
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Correlation between HRQOL and NCF: 
Evaluation of the HRQOL and NCF status of the twenty patients over the study period 
has shown a remarkable and dynamic correlation between the two parameters. There 
was a statistically significant correlation between HRQOL and NCF in the first and 
third time points according to Pearson’s correlation calculation.  
The correlation between NCF and HRQOL is evident in the following radar graphs: 
Figure 37: NCF and HRQOL scores – Pre Radiotherapy: 
 
 
It is quite evident from the Figure 37, patients – UID 1, 3, 5 and 15 had comparatively 
low NCF scores and their corresponding HRQOL scores were also low compared to 
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other patients. On the other hand, patients with good NCF scores had the best HRQOL 
results. The correlation between NCF and HRQOL was statistically significant with p 
value < 0.0002 (Table 24). 
 
Figure 38: NCF and HRQOL scores – Post Radiotherapy: 
 
 
In the assessment Post Radiotherapy, a similar pattern was observed. The patients – 
UID 1, 5 and 15 continued to have comparatively low NCF and correspondingly low 
HRQOL scores (Figure 38). On the contrary, the patient - UID 3 showed a good 
response with improvement in NCF and HRQOL scores. The patients - UID 7 and 
UID 9 had marginal improvement in their NCF scores, which was reflected in their 
remarkably better HRQOL scores. It is evident that there was no pronounced 
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deterioration in the quality of life in other patients. However the correlation between 
NCF and HRQOL was not statistically significant with p value < 0.17 (Table 24). 
 
Figure 39: NCF and HRQOL scores – Post Adjuvant chemotherapy: 
 
 
In the assessment Post adjuvant chemotherapy, three patients – UID 1, 5 and 15 was 
noticed to have low NCF scores and correspondingly low HRQOL scores, whereas the 
patient, UID 3 showed a minimal improvement in NCF and HRQOL scores (Figure 
39). It is evident that there was no pronounced deterioration in the quality of life in 
other patients. There was statistically significant correlation between NCF and 
HRQOL with p value < 0.0001 (Table 24). 
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Table 24: Statistical significance of correlation between NCF and HRQOL: 
Correlation between NCF and HRQOL p Value 
Pre Radiotherapy < 0.0002 
Post Radiotherapy < 0.1693 
Post Adjuvant Chemotherapy < 0.0001 
 
Effect of Age, Tumour location and Type of Surgery on HRQOL and NCF 
Age: 
Though not statistically significant, it was noted that the mean HRQOL scores were 
lower in patients with age >50 years where as corresponding the NCF scores were 
slightly better (Table 25). 
Table 25: Age - Mean Scores 
MEAN SCORE 
Age  Total QOL 
- 1st 
Total QOL 
- 2nd 
Total QOL 
- 3rd 
Total NCF 
- 1st 
Total NCF 
– 2nd 
Total NCF 
– 3rd 
<50 -18.00 9.56 26.88 20.63 25.88 35.31 
>50 -21.75 10.75 19.25 24.25 31.50 34.00 
 
Tumour location – Laterality: 
Though not statistically significant, it was noted that left sided tumours tend to have 
lower neurocognitive status (Table 26). 
Table 26: Tumour Location - Mean Score 
MEAN SCORE 
Location Total 
QOL - 1st 
Total 
QOL - 2nd 
Total 
QOL - 3rd 
Total NCF 
- 1st 
Total NCF 
– 2nd 
Total NCF 
– 3rd 
Right -18.55 8.82 25.27 23.45 28.45 36.55 
Left -19.00 11.00 25.44 18.78 25.22 33.22 
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Type of Surgery: 
Though not statistically significant, it was evident that patients who underwent gross 
tumour resection had better quality life and neurocognitive function scores (Table 27). 
Table 27: Type of Surgery - Mean Score 
MEAN SCORE 
Surgery Total 
QOL - 1st 
Total 
QOL - 2nd 
Total 
QOL - 3rd 
Total NCF 
- 1st 
Total NCF 
– 2nd 
Total NCF 
– 3rd 
GTR -15.90 10.00 29.90 21.70 27.50 36.60 
STR -21.60 9.60 20.80 21.00 26.50 33.50 
 
DISCUSSION 
 
In this prospective observational study, we evaluated the patient reported Health 
related quality of life (HRQOL) and Neurocognitive functioning (NCF) in high grade 
glioma patients at three different time points – before starting radiotherapy, after 
radiotherapy and after completion of adjuvant chemotherapy. Our secondary 
objectives were to assess the correlation between HRQOL and NCF and to evaluate 
the predictive potential of impairment in HRQOL and NCF as objective markers for 
disease recurrence.  
 
Systematic reviews on high grade glioma by Ostrom el al and DeAngelis et al has 
shown that the median age of presentation of Grade 4 glioma is >70 years and that of 
Grade 3 glioma is 55-60 years.(2)But most of our patients were young, with median 
age of 42 years. In our study, 75% patients were males and 25% were females. A 
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recent study by Yang and Warrington et al has reported the sex differences in high 
grade glioma and according to it male: female ratio is 1.6-2.0: 1.(66) 
 
In our study, 85% of the patients had Karnofsky Performance Score of 90 and none of 
them had score <70 as per the inclusion criteria of the study. Similar findings were 
noted in the studies done by Bosma et al, where the mean KPS was 80 and in an 
Indian study by Anand et al, most of the patients have KPS >70.(36,67) In an article 
published by Sachsenheimer et al in 1992, it was mentioned that patients who have 
KPS <70 at presentation is associated with poorer outcomes whereas the NCCN 2018 
has mentioned that KPS <60 is associated with poor prognosis.(35) 
 
Most of the patients presented with complaints of headache or vomiting (60%) or 
seizures (40%). A clinical review on malignant gliomas by Omuro and DeAngelis has 
demonstrated that headache is the presenting symptom in about 50% of the patients 
followed by seizures (20-40%).(3) 
 
All the patients in our study underwent maximal safe resection, of which 45% had 
gross tumour resection. All the patients received adjuvant treatment as per the current 
standard recommendation, i.e. focal radiotherapy with concurrent Temozolomide 
followed by adjuvant Temozolomide for 6 months; however, one patient did not take 
adjuvant Temozolomide.   
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Evaluation of HRQOL was done with FACT-Br questionnaire, which is a 
comprehensive tool to assess the psychosocial, functional status and important 
neuropathological symptoms. HRQOL was assessed with respect to their physical, 
social, emotional, functional well-being and certain additional concerns related to 
neurological symptoms and some skilled activities of daily life. NCF was assessed 
using MMSE and MOCA questionnaires which have high sensitivity and specificity to 
detect cognitive impairments at different domains. Literature review has shown there 
were only few published studies using the aforementioned combination of 
questionnaires for HRQOL and NCF. 
 
Our study has shown a progressive and statistically significant improvement in overall 
HRQOL (p <0.001) and NCF (p <0.000) for 80% of the patients. However there was 
decline in both the scores for 20% patients who were subsequently diagnosed to have 
disease recurrence. All the subscales in FACT-Br showed statistically significant 
improvement over the period of study though the follow up period was small. Physical 
well-being of the patients has shown a significant improvement from baseline 
reporting in 95% of the patients (p <0.001), whereas it has deteriorated after showing 
improvement post radiotherapy in one of the patients who developed disease 
recurrence later. This was in agreement with the finding demonstrated by Porter et al 
and Bosma et al, whereas the later author has used SF-36 questionnaire also for 
assessment.(36,62,68) Social well-being scores consistently showed an improving 
trend with statistical significance (p <0.007) in all the patients which is a reflection of 
the support they got from family and friends. This was in agreement with the study by 
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Porter et al and Cheng et al where social well-beings scores were significantly higher 
compared to other parameters. In the study by Porter et al, the mean social wellbeing 
score at baseline was 21.10 (SD = 3.6) whereas in our study it was 22.9 (SD = 2.15). 
The scores showed progressive improvement in the Porter et al study with significant 
Cronbach’s alpha co-efficient of 0.82.(68,69) 
 
Similar observation was noted with respect to functional (p <0.001) and emotional 
well-being (p <0.000) where 80% of the patients showed a progressive improvement 
in scores and the four patients (20%) who had disease recurrence performed poorly. 
Worst scores were noted to be in their concern about death and impairment in 
performing routine household activities. Studies by Porter et al and Chang et al has 
shown similar results in which the former study has mentioned that most of the 
patients with high grade glioma tend to have lower scores in these two aspects of 
quality of life assessment which was noted to be 50.7 to 52.% of the total subscale 
score.(34,68) 
 
Neurocognitive functioning of the patients in our study has shown a gradual 
improvement over the period of time in 80% of the patients though it was subtle in 
some of the patients (p <0.000). Disease recurrence can be attributed to the cause of 
decline in performance of rest of the patients. Hilverda et al shown that 
neurocognition improves in high grade glioma patients receiving adjuvant 
radiotherapy and chemotherapy with Temozolomide.(61) Also in the largest 
randomised trial on high grade gliomas till date, Taphroon and Stupp have shown that 
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quality of life did not deteriorate in 63% patients (p=0.0076) receiving adjuvant 
radiotherapy and Temozolomide.(44) 
 
Our study was consistent with findings in the published data by Henrikkson et al, 
where it is clearly demonstrated that there is statistically significant direct correlation 
between neurocognition and quality of life, where surgery and adjuvant treatment 
improve the outcomes and progression of disease hampers it.(57) In our study, the 
direct correlation was significant in pre radiotherapy period (p <0.002) and post 
chemotherapy period (p <0.001) however post radiotherapy evaluation also showed 
direct correlation but it was not statistically significant (p <0.169). Bosma et al has 
also shown that decline in neurocognition is mostly due to disease recurrence.(62)  
 
During our study period, 20% of the patients had disease recurrence which was 
radiologically proven and all these patients consistently had poor scores in 
neurocognition and quality of life assessment throughout the study. The direct 
correlation between neurocognition and quality of life was also cited in a prospective 
study by Brown et al.(39) According to Bosma et al and Archibald et al, long term 
follow-up, at least 16-24 months, is required to assess the neurocognitive functioning 
of brain tumour patients, but our median follow up period was 10 months.(62,70) 
 
In agreement with the review of literature, older patients tend to have lower quality of 
life compared to their young counterparts. In the prospective study by Brown et al and 
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another published data by Bosma et al has shown the statistical significance of 
younger age in determining better prognosis of high grade glioma.(39,62) 
 
Our study has shown that left sided tumours are associated with more neurocognitive 
dysfunction, which correlates with the findings of Hom and Reitan et al and Scheibel 
et al,(52,71) whereas Salo et al has commented from his study that right sided tumours 
are associated with poorer outcomes.(54)Another observation made was the 
comparatively lower scores noted in patients with left sided tumours which was in 
agreement with the findings demonstrated by Scheibel et al.(71) 
 
According to Chang et al, gross tumour resection has a significant prognostic role, 
improving neurological status and also improves the quality of life. Global QOL was 
improved by 10 points in gross tumour resection compared with 6 points in partial 
resection or biopsy (p <0.05).(34) Consistent with findings in the literature our study 
has shown that gross tumour resection is superior to sub-total resection in terms of 
neurocognitive functioning and quality of life. 
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LIMITATIONS OF OUR STUDY 
1. The main limitation of our study was shorter follow up owing to the time 
constraints. Review of literature has shown that, long term follow up is needed 
to evaluate the neurocognitive status and quality of life.  
2. The sample size of our study was 13 patients based on statistical calculation 
and we recruited 20 patients. However a large cohort of patients is needed for 
detailed subgroup analysis such as presenting symptoms, post-operative 
complications, molecular biology, technique of radiotherapy and effect 
modifiers affecting the HRQOL and NCF. 
3. The baseline scores of patients, i.e. at the time of presentation or pre-surgery, 
were not assessed in our study.  
4. Also, in our study we did not assess the quality of life from caregivers’ 
perspective; which was noted significant in some of the published data. 
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CONCLUSION 
1. Patient reported health related quality of life is an integral part of 
comprehensive patient care and treatment outcomes, in addition to classical 
parameters such as survival rates and performance status.  
2. Improvement in health related quality of life has a significant prognostic value 
and gives a sense of well-being for the patients and care givers.  
3. Assessment of patient reported health related quality of life using standard 
questionnaires can be incorporated into routine clinical practice where it will 
help to establish a good rapport between patients and physician, give a chance 
of objective assessment of treatment response and also deterioration in quality 
of life will remain as a marker of disease progression. 
4. In patients with high grade glioma, post-operative radiotherapy and 
chemotherapy improves the HRQOL and NCF.  
5. The decline in HRQOL and NCF in a post treatment period is directly related 
to disease recurrence.  
6. High grade glioma patients will have neurocognitive dysfunction which is 
multifactorial; hence neurocognitive function assessment has to be included in 
regular clinical practice.  
7. There is a direct correlation between neurocognition and quality of life in high 
grade glioma patients especially in long term survivors. 
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ANNEXURE 2 - INFORMATION SHEET AND CONSENT FORM 
Study Title: Patient reported health related quality of life and neurocognitive 
function assessment in patients with high grade glioma  
Primary brain tumours are cancers that originate in brain classified according to their 
appearance under a microscope as low grade (grade I and II) with diffuse 
astrocytomas, pliocytic astrocytomas, oligodendrogliomas, and mixed gliomas as 
common subtypes and high grade (grade III and IV).  It has been estimated in West 
that the chances of having glioma is about 5.26 in 100,000 making it a relatively rare 
form of cancer. Glioma is found mostly among men, often in their 70s and 80s, though 
it has in recent years began appearing much more frequently in 50 year olds and even 
younger. Gliomas are ranked by cell types and in grades from 1 to 4 with grade 1 on 
scale published by the World Health Organization being the most benign and stage 4 
the most aggressive. Stage 1 and 2 gliomas involve differentiated cells and can often 
be left untreated, or minimally treated, and have excellent survival rates, as serious 
cancers. Stage 3 glioma normally involves astrocytes and the disease is referred to as 
anaplastic asrocytoma. Stage 4 glioma is referred to as glioblastoma – IDH mutant and 
wild type. The main modalities of treatment for cure of high grade glioma include 
surgery, radiation therapy and/or chemotherapy. 
In the course of their disease, most high grade glioma patients are confronted with 
neurocognitive deficits, subsequently affecting their health-related quality of life 
(HRQOL). Neurocognitive functioning in glioma patients can be affected by the 
tumour, tumour-related epilepsy, by treatment with neurosurgery, radiotherapy, 
chemotherapy, antiepileptics, or corticosteroids. 
This study aims at assessing the effects of radiation therapy to brain in patients with 
high grade glioma. It assesses the quality of life and neurocognitive functioning in 
patients undergoing radiation therapy to brain thorough separate questionnaires. 
Neurocognitive summary measures were calculated to detect possible deficits in the 
domains of (1) information processing, (2) psychomotor function, (3) attention, (4) 
verbal memory, (5) working memory, and (6) executive functioning. 
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You are being requested to participate in this study assessing the effects of radiation on 
brain and the quality of life issues. 
If you take part what you will have to do? 
You will be assessed by three separate standard questionnaires regarding 
neurocognitive functioning and health related quality of life at three points of time-  
1. Before starting  radiation therapy 
2. After completion of radiation therapy 
3. When you come for first follow up after completing adjuvant chemotherapy 
Will I have to bear any extra expenses because I am part of this study? 
No, you will not have to bear any extra expense for being a part of this study. No 
additional tests or imaging is required for this study. 
Can I withdraw from the study after it starts? 
Yes. Your participation in the study is absolutely voluntary. If you withdraw from the 
study during the treatment, it will not affect your treatment in any way. 
What are the benefits of this study? 
There is scarce prospective data regarding health related quality of life and 
neurocognitive function status in high grade glioma patients undergoing 
chemoradiotherapy post-operatively in the Indian scenario. This study helps to assess 
the patient reported quality of life before, during and after treatment helping cross 
sectional assessment of issues. Also this study help in picking up disease recurrence 
based on change in quality of life or neurocognitive impairment before evident clinical 
or radiological features of recurrence set in. 
Will your personal details be kept confidential? 
Yes. The results of the study when published in any journal would not reveal your 
name or personal information in any form. 
For any further queries, you may please contact:  
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Informed Consent form to participate in a research study  
Study Title: Patient reported health related quality of life and neurocognitive function 
assessment in high grade glioma - pre radiation therapy and post radiation therapy 
Study Number: ____________ 
Subject’s Initials: __________________  
Subject’s Name: _________________________________________ 
Date of Birth / Age: ___________________________ 
(i) I confirm that I have read and understood the information sheet dated 
____________ for the above study and have had the opportunity to ask 
questions[  ] 
(ii) I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or 
legal rights being affected. [  ] 
(iii)  I understand that the Ethics Committee and the regulatory authorities will not 
need my permission to look at my health records both in respect of the current 
study and any further research that may be conducted in relation to it, even if I 
withdraw from the trial. I agree to this access. However, I understand that my 
identity will not be revealed in any information released to third parties or 
published. [  ] 
(iv)  I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purpose(s). [  ] 
(v)  I agree to take part in the above study. [  ] 
Signature (or Thumb impression) of the Subject/Legally Acceptable  
Date: _____/_____/______ 
Signatory’s Name: _________________________________         Signature:  
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Or 
 
 
 
 
Representative: _________________ 
Date: _____/_____/______ 
 
Signatory’s Name: _________________________________ 
Signature of the Investigator: _______________________ 
Date: _____/_____/______ 
Study Investigator’s Name: _________________________ 
Signature or thumb impression of the Witness: ___________________________ 
Date: _____/_____/_______ 
Name & Address of the Witness: ______________________________ 
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ANNEXURE 3 - QUESTIONNAIRES USED IN THE STUDY: 
ANNEXURE 3A –FACT Br
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